Kristian Reich

CSO Kristian Reich sells 150,000 shares of MLTX across 3 days for $2.9M via pre-arranged 10b5-1 plan

Kristian Reich, Chief Scientific Officer of MoonLake Immunotherapeutics, executed 3 separate sales totaling 150,000 shares for $2,851,000.00 between 2026-06-15 and 2026-06-17. The transaction is part of a pre-arranged 10b5-1 trading plan adopted on 2026-03-10, meaning the sales were scheduled rather than discretionary. Post-transaction, Reich retains 2,824,551 shares, representing a -5.0% reduction from his 2,974,551 pre-transaction holdings. His prior trades at MLTX show mixed outcomes: two recent sells in December 2025 posted 30-day returns of -0.6% and -25.1%, while three trades in February 2024 each posted -8.7% 30-day returns; his cross-ticker track record across 16 prior sells averaged -14.0% 30-day return. MoonLake reported a full-year net income of $-69,707,000.00, indicating the company remains unprofitable.

CSO Reich Kristian sold 202,908 shares (100% of holdings) for $3,012,462.44, exiting position entirely as stock tumbles 76.4% from 52-week high.

Reich Kristian, Chief Scientific Officer, executed two separate sales totaling 202.9K shares for $3.0M, completely liquidating his stake at an average price of $14.85. This comes as MLTX trades 76.4% below its 52-week high of $61.99 and amid a -73.1% decline over the past 90 days, despite a +35.0% rebound in the last 30 days. Notably, Reich's cross-ticker track record shows a 100.00% well-timed rate on 14 prior sells with an average 90-day return of -30.2%, and all 5 of his prior MLTX sells were also well-timed at the 90-day mark. The complete divestiture by a CSO of an unprofitable company (net income -$69.7M) following a sustained price collapse raises questions about insider perspective on near-term prospects.